πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

8,395 results for β€œLa” Clear

  1. telavancin

    CUMBERLAND PHARMACEUTICALS INC

    Kidney Diseases

    phase 1 small molecule completed

    1 trial

  2. tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  3. transcutaneous auricular vagus nerve stimulation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy Participants

    phase 1 other active

    1 trial

  4. trastuzumab [Herceptin]

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  5. treprostinil diethanolamine

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 1 small molecule completed

    2 trials

  6. ucMSCs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bronchopulmonary Dysplasia

    phase 1 mab active

    1 trial

  7. zelenirstat

    United Therapeutics Europe Ltd

    Relapsed Adult AML

    phase 1 small molecule active

    1 trial

  8. Ξ±-lactalbumin vaccine

    Anixa Biosciences Inc

    Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer

    phase 1 mab active

    1 trial

  9. ​​A Phase 1, Open-Label, Multiple-Part Trial to Evaluate the Drug-Drug Interaction Potential of PRAX-628 in Healthy Participants​

    Chongqing Precision Biotech Co., Ltd

    Epilepsy

    phase 1 other active

    1 trial

  10. β€žINSIGHTβ€œ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors

    The George Institute

    Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)

    phase 1 other active

    1 trial

  11. -, -, SULFAMETHOXAZOLE AND TRIMETHOPRIM

    Pari Pharma GmbH

    Pyelonephritis, Kidney Transplant recipients

    approved small molecule active

    1 trial

  12. 0.3% ropivacaine and 50 ΞΌg dexmedetomidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Free Flap Reconstruction

    approved small molecule active

    1 trial

  13. 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.

    Takeda

    Prostate or Bladder Cancer

    approved small molecule completed

    1 trial

  14. 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen

    Pacira Ireland Limited

    Elective Cesarean Section

    approved small molecule completed

    1 trial

  15. A-101 Topical Solution

    Aclaris Therapeutics

    Seborrheic Keratosis

    approved small molecule completed

    1 trial

  16. ABBV-066, DEUCRAVACITINIB

    AbbVie Deutschland GmbH & Co. KG

    Plaque Psoriasis

    approved small molecule active

    1 trial

  17. ACETYLSALICYLIC ACID

    The George Institute

    Obstetrics – Preeclampsia

    approved small molecule active

    1 trial

  18. ADVAGRAF

    Astellas Pharma Inc

    Renal Transplantation

    approved small molecule completed

    1 trial

  19. AGAMREE 40 mg/ml oral suspension

    Lacuna Pharma Pty Ltd

    Duchenne Muscular Dystrophy

    approved small molecule active

    1 trial

  20. AL (Coartem)

    United Therapeutics Europe Ltd

    Malaria

    approved small molecule completed

    1 trial

  21. ALA

    The First People's Hospital of Lianyungang

    Actinic Keratoses

    approved small molecule active

    1 trial

  22. AMINOHIPPURIC ACID , IOTALAMATE MEGLUMINE, Adrenaline CF 1 mg/ml, oplossing voor injectie, OMNIPAQUE 300 mg I/ml, Tavegyl 1 mg/ml, oplossing voor injectie, SODIUM IOTALAMATE (125I)

    Disc Medicine

    Chronic Kidney Disease Kidney Failure

    approved small molecule active

    1 trial

  23. AMOXICILLIN

    Pari Pharma GmbH

    Adults diagnosed with lower limbs erysipelas

    approved small molecule active

    1 trial

  24. AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFEPIME , CEFOTAXIME, SPIRAMYCIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

    Pari Pharma GmbH

    EA-COPD (with mechanical ventilation, invasive or non-invasive, or high-flow nasal oxygen therapy).

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources